These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 36501086)
21. Iron Deficiency Impacts Diastolic Function, Aerobic Exercise Capacity, and Patient Phenotyping in Heart Failure With Preserved Ejection Fraction: A Subanalysis of the OptimEx-Clin Study. Gevaert AB; Mueller S; Winzer EB; Duvinage A; Van de Heyning CM; Pieske-Kraigher E; Beckers PJ; Edelmann F; Wisløff U; Pieske B; Adams V; Halle M; Van Craenenbroeck EM; Front Physiol; 2021; 12():757268. PubMed ID: 35222057 [TBL] [Abstract][Full Text] [Related]
22. Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial. Lewis GD; Malhotra R; Hernandez AF; McNulty SE; Smith A; Felker GM; Tang WHW; LaRue SJ; Redfield MM; Semigran MJ; Givertz MM; Van Buren P; Whellan D; Anstrom KJ; Shah MR; Desvigne-Nickens P; Butler J; Braunwald E; JAMA; 2017 May; 317(19):1958-1966. PubMed ID: 28510680 [TBL] [Abstract][Full Text] [Related]
23. Ferric carboxymaltose in patients with pulmonary arterial hypertension and iron deficiency: a long-term study. Kramer T; Wissmüller M; Natsina K; Gerhardt F; Ten Freyhaus H; Dumitrescu D; Viethen T; Hellmich M; Baldus S; Rosenkranz S J Cachexia Sarcopenia Muscle; 2021 Dec; 12(6):1501-1512. PubMed ID: 34498427 [TBL] [Abstract][Full Text] [Related]
24. Iron Deficiency: Impact on Functional Capacity and Quality of Life in Heart Failure with Preserved Ejection Fraction. Alcaide-Aldeano A; Garay A; Alcoberro L; Jiménez-Marrero S; Yun S; Tajes M; García-Romero E; Díez-López C; González-Costello J; Mateus-Porta G; Cainzos-Achirica M; Enjuanes C; Comín-Colet J; Moliner P J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32331365 [TBL] [Abstract][Full Text] [Related]
25. Iron replacement therapy in heart failure: a literature review. Ismahel H; Ismahel N Egypt Heart J; 2021 Sep; 73(1):85. PubMed ID: 34568981 [TBL] [Abstract][Full Text] [Related]
26. Impact of change in iron status over time on clinical outcomes in heart failure according to ejection fraction phenotype. Fitzsimons S; Yeo TJ; Ling LH; Sim D; Leong KTG; Yeo PSD; Ong HY; Jaufeerally F; Ng TP; Poppe K; Lund M; Devlin G; Troughton R; Lam CSP; Richards AM; Doughty RN ESC Heart Fail; 2021 Dec; 8(6):4572-4583. PubMed ID: 34592056 [TBL] [Abstract][Full Text] [Related]
27. Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the Swedish Heart Failure Registry. Becher PM; Schrage B; Benson L; Fudim M; Corovic Cabrera C; Dahlström U; Rosano GMC; Jankowska EA; Anker SD; Lund LH; Savarese G Eur J Heart Fail; 2021 Nov; 23(11):1844-1854. PubMed ID: 34476878 [TBL] [Abstract][Full Text] [Related]
28. Anaemia, iron deficiency and heart failure in 2020: facts and numbers. Chopra VK; Anker SD ESC Heart Fail; 2020 Oct; 7(5):2007-2011. PubMed ID: 32602663 [TBL] [Abstract][Full Text] [Related]
29. Impact of ferric carboxymaltose for iron deficiency at discharge after heart failure hospitalization: a European multinational economic evaluation. McEwan P; Harrison C; Binnie R; Lewis RD; Cohen-Solal A; Lund LH; Ohlsson M; von Haehling S; Comin-Colet J; Pascual-Figal DA; Wächter S; Dorigotti F; de Arellano AR; Ponikowski P; Jankowska EA Eur J Heart Fail; 2023 Mar; 25(3):389-398. PubMed ID: 36718652 [TBL] [Abstract][Full Text] [Related]
30. Iron deficiency impacts prognosis but less exercise capacity in heart failure with preserved ejection fraction. Barandiarán Aizpurua A; Sanders-van Wijk S; Brunner-La Rocca HP; Henkens MTHM; Weerts J; Spanjers MHA; Knackstedt C; van Empel VPM ESC Heart Fail; 2021 Apr; 8(2):1304-1313. PubMed ID: 33522131 [TBL] [Abstract][Full Text] [Related]
31. Exercise training response according to baseline ferrokinetics in heart failure with preserved ejection fraction: A substudy of the TRAINING-HF trial. Palau P; López L; Domínguez E; de La Espriella R; Campuzano R; Castro A; Miñana G; Fernández-Cisnal A; Sanchis J; Núñez J J Cachexia Sarcopenia Muscle; 2024 Apr; 15(2):681-689. PubMed ID: 38225218 [TBL] [Abstract][Full Text] [Related]
32. The effect of intravenous ferric carboxymaltose on red cell distribution width: a subanalysis of the FAIR-HF study. Van Craenenbroeck EM; Conraads VM; Greenlaw N; Gaudesius G; Mori C; Ponikowski P; Anker SD Eur J Heart Fail; 2013 Jul; 15(7):756-62. PubMed ID: 23639779 [TBL] [Abstract][Full Text] [Related]
33. Iron Deficiency, Anemia, and Iron Supplementation in Patients With Heart Failure: A Population-Level Study. Wahid M; Islam S; Sepehrvand N; Dover DC; McAlister FA; Kaul P; Ezekowitz JA Circ Heart Fail; 2024 Apr; 17(4):e011351. PubMed ID: 38572652 [TBL] [Abstract][Full Text] [Related]
34. Ferric Carboxymaltose in Heart Failure with Iron Deficiency. Mentz RJ; Garg J; Rockhold FW; Butler J; De Pasquale CG; Ezekowitz JA; Lewis GD; O'Meara E; Ponikowski P; Troughton RW; Wong YW; She L; Harrington J; Adamczyk R; Blackman N; Hernandez AF; N Engl J Med; 2023 Sep; 389(11):975-986. PubMed ID: 37632463 [TBL] [Abstract][Full Text] [Related]
35. Ferric Carboxymaltose in Iron-Deficient Patients with Hospitalized Heart Failure and Reduced Kidney Function. Macdougall IC; Ponikowski P; Stack AG; Wheeler DC; Anker SD; Butler J; Filippatos G; Göhring UM; Kirwan BA; Kumpeson V; Metra M; Rosano G; Ruschitzka F; van der Meer P; Wächter S; Jankowska EA Clin J Am Soc Nephrol; 2023 Sep; 18(9):1124-1134. PubMed ID: 37382961 [TBL] [Abstract][Full Text] [Related]
36. Systematic review and meta-analysis of intravenous iron-carbohydrate complexes in HFrEF patients with iron deficiency. Sindone A; Doehner W; Comin-Colet J ESC Heart Fail; 2023 Feb; 10(1):44-56. PubMed ID: 36178088 [TBL] [Abstract][Full Text] [Related]
37. Iron Deficiency in Heart Failure with Reduced Ejection Fraction: Pathophysiology, Diagnosis and Treatment. Pereira GAR; Beck-da-Silva L Arq Bras Cardiol; 2022 Mar; 118(3):646-654. PubMed ID: 35319614 [TBL] [Abstract][Full Text] [Related]
38. Rationale and design of the IRON-CRT trial: effect of intravenous ferric carboxymaltose on reverse remodelling following cardiac resynchronization therapy. Martens P; Dupont M; Dauw J; Somers F; Herbots L; Timmermans P; Verwerft J; Mullens W ESC Heart Fail; 2019 Dec; 6(6):1208-1215. PubMed ID: 31562751 [TBL] [Abstract][Full Text] [Related]
39. Indirect comparison between ferric carboxymaltose and oral iron replacement in heart failure with reduced ejection fraction: a network meta-analysis. Sciatti E; Nesti U; Di Lenarda A Monaldi Arch Chest Dis; 2021 Mar; 91(3):. PubMed ID: 33794590 [TBL] [Abstract][Full Text] [Related]
40. Iron Deficiency: A New Target for Patients With Heart Failure. Rizzo C; Carbonara R; Ruggieri R; Passantino A; Scrutinio D Front Cardiovasc Med; 2021; 8():709872. PubMed ID: 34447793 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]